US 12285406 B1Patent grantUnited States

Selenide Compounds for Oncology Screening

Official patent title

Method of treating cancer with a selenide

Arabic title: طريقة لعلاج السرطان باستخدام سيلينيد

Invention

Problem

Prostate cancer, pharyngeal squamous carcinoma, and triple-negative breast cancer require additional therapeutic candidates, but any new selenide must be evaluated for efficacy, selectivity, and toxicity.

Why it matters

A compound linked to defined apoptosis pathways may support focused preclinical research, although the patent publication does not establish benefit or safety in subjects.

Approach

The claims administer a compound of Formula I, or a pharmaceutically acceptable salt, for three selected cancers and associate it with upregulation or downregulation of apoptosis-related genes.

Who may benefit

Potential beneficiaries include medicinal-chemistry groups, oncology researchers, pharmaceutical discovery teams, formulation scientists, and technology-transfer partners evaluating early-stage therapeutic compounds.

Potential value

The disclosure narrows its principal treatment claim to prostate cancer, pharynx squamous carcinoma, and triple-negative breast cancer while retaining defined molecular targets, dose range, and administration routes.

Background

Cancer treatment can damage healthy cells and cause serious adverse effects, and triple-negative breast cancer has relatively few targeted options. Apoptosis is regulated by proteins and genes including p53, BAX, caspases, BCL-2, MMP2, and MMP9. The patent proposes a substituted selenide-containing compound family and pharmaceutically acceptable salts for selected cancers. It also describes broader inflammation and formulation embodiments in the specification, but the assigned evidence does not document animal efficacy, human trials, pharmacokinetics, toxicology, manufacturing readiness, or regulatory status.

Technology overview

Formula I permits independent substitutions at R1–R4, R5A–R7A, and R5B–R7B from hydrogen, halogen, nitro, cyano, hydroxyl, alkoxy, and optionally substituted alkyl, cycloalkyl, arylalkyl, or aryl groups. The principal claim covers prostate cancer, pharynx squamous carcinoma, and triple-negative breast cancer. Dependent claims name Compound II, upregulation of p53, BAX, and Caspases 3, 6, 8, or 9, downregulation of BCL-2, MMP2, or MMP9, administration by several routes, and a dosage range of 0.1–1000 mg/kg.

Potential applications

Potential use in preclinical screening for the three claimed cancer types.
Potential use in laboratory studies of apoptosis-associated gene regulation.
Potential use in medicinal-chemistry optimization of selenide analogues.
Potential use in formulation and route-of-administration research.

Evidence-supported advantages

Focuses the principal claim on three named cancer types.
Defines a broad substitution pattern and a specific Compound II embodiment.
Links the claimed method to named pro- and anti-apoptotic genes.
Covers several administration routes and a stated dosage range.

Development stage

Patent publication; development stage not independently verified.

Commercial opportunity

The claims may support licensing into a discovery-stage oncology program after evidence generation. Required work includes structure confirmation, reproducible synthesis, analytical purity, cell-line efficacy, normal-cell selectivity, mechanism validation, dose-response, selenium toxicology, pharmacokinetics, formulation, animal studies, clinical trials, manufacturing controls, and regulatory review.

Patent classifications

WIPO IPC

A61K31/4035Preparations for medical, dental or toiletry purposes
A61P29/00Specific therapeutic activity of chemical compounds or medicinal preparations

CPC

A61P29/00Specific therapeutic activity of chemical compounds or medicinal preparations
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
A61K31/4035Preparations for medical, dental or toiletry purposes

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorAhmed A. Al-Karmalawy
InventorAyman Abo Elmaaty
InventorMarwa Sharaky

Keywords

selenide
Formula I
Compound II
prostate cancer
triple-negative breast cancer
apoptosis
caspases
medicinal chemistry

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.